Delving into the Latest Updates on Farletuzumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-GP-3 humanised mAb, Anti-GP3 humanised monoclonal antibody, Farletuzumab (genetical recombination) (JAN)

+ [2]

Target

FOLR1

Action

antagonists

Mechanism

FOLR1 antagonists(Folate receptor alpha antagonists)

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseUrogenital Diseases+ [4]

Active Indication-

Inactive Indication

Adenocarcinoma of LungFallopian Tube CarcinomaNon-Functioning Pituitary Neuroendocrine Tumor+ [8]

Originator Organization

Morphotek, Inc.

Active Organization-

Inactive Organization

Eisai Europe Ltd.

Morphotek, Inc.

Eisai, Inc.

+ [1]

License Organization

Eisai, Inc.

Eurofarma Laboratórios SA

Morphotek, Inc.

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Sequence Code 4703059H

Source: *****

Sequence Code 4703062L

Source: *****

The primary objective of this study is to compare the effect of farletuzumab versus placebo in combination with either a platinum agent (carboplatin) with paclitaxel or a platinum agent (carboplatin or cisplatin) with pemetrexed followed by farletuzumab or placebo on investigator-assessed progression free survival (PFS) as determined by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 or definitive clinical disease progression (eg, new occurrence of positive fluid cytology) in chemotherapy naive participants with folate receptoralpha (FRA)-expressing Stage IV adenocarcinoma of the lung.

Start Date27 Jun 2011

Sponsor / Collaborator

Morphotek, Inc.

100 Clinical Results associated with Farletuzumab

Login to view more data

100 Translational Medicine associated with Farletuzumab

Login to view more data

100 Patents (Medical) associated with Farletuzumab

Login to view more data

40

Literatures (Medical) associated with Farletuzumab

01 Dec 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Comprehensive assessments of pharmacokinetics and immunogenicity of farletuzumab ecteribulin, a novel antibody-drug conjugate against tumors expressing folate receptor α, in monkeys

Article

Author: Mano, Yuji ; Fernando, Shawn

Farletuzumab ecteribulin (MORAb-202) is a novel antibody-drug conjugate (ADC) comprising farletuzumab and eribulin with a cathepsin-B cleavable linker, currently under development for tumors expressing folate receptor α. It is crucial to comprehend the pharmacokinetics (PK) of MORAb-202 in monkeys to enhance the accuracy of PK prediction in humans. To this end, a series of assays were devised for the total antibody (Tab) as the sum of conjugated and unconjugated antibodies, the conjugated antibody as the ADC, and the unconjugated eribulin (payload) by a ligand binding assay (LBA) and liquid chromatography with tandem mass spectrometry. The LBA by Gyrolab was employed for the quantification of Tab and ADC. Additionally, a semi-quantitative assay for anti-drug antibody (ADA) was developed using the LBA for the immunogenicity assessment. The quantifiable range for ADC and Tab in monkey serum was from 0.4 and 4 µg/mL, respectively, while eribulin was quantified from 0.2 ng/mL. The aforementioned methodologies were subsequently validated and employed in a PK study in monkeys. The accuracy and precision of the assay were within the criteria. Following intravenous administration, the PK profiles of Tab and ADC were similar, while minimal levels of eribulin. No ADA against MORAb-202 was detected in postdose samples.

12 Nov 2024·Cureus Journal of Medical Science

Efficacy and Safety of Farletuzumab in Ovarian Cancer: A Systematic Review and Single-Arm Meta-Analysis

Review

Author: Helal, Abdallah A ; Abd-ElGawad, Mohamed ; Darwish, Moaz Yasser ; Mohamed, Nada Shaaban ; Elrashedy, Asmaa Ahmed ; Fayoud, Aya M ; Nada, Eman Ayman

Folate receptor alpha (FRα) has emerged as a promising target in the treatment of ovarian cancer, with farletuzumab, a humanized monoclonal antibody targeting FRα, showing potential in clinical settings. This systematic review and single-arm meta-analysis aimed to evaluate the efficacy and safety of farletuzumab in patients with solid tumors, particularly ovarian cancer. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a thorough search across PubMed, the Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) for clinical trials assessing farletuzumab in solid tumors. Data were extracted on study characteristics, patient demographics, treatment regimens, and efficacy outcomes including progression-free survival (PFS), overall survival (OS), response rates, and adverse events (AEs). The pooled analyses were performed using the Open Meta-Analyst software. In total, seven prospective studies were included, covering various farletuzumab regimens in ovarian cancer and other solid tumors. The pooled PFS was 10.5 months (95% CI: 8, 15.7) across three studies involving 925 patients, while the pooled OS was 36.7 months (95% CI: 26.6, 35) in two studies with 881 patients. Treatment response rates indicated a partial response in 55.25% of patients and stable disease in 28.68% of cases. Gastrointestinal and hematological AEs were frequently reported, with nausea (52.14%), neutropenia (50.65%), and anemia (39.76%) being the most common. Farletuzumab appears to offer a promising efficacy profile, particularly in ovarian cancer, with notable improvements in disease progression and survival. However, the treatment is associated with a high incidence of gastrointestinal and hematological AEs, raising the need for careful patient selection. Further studies are required to refine the therapeutic regimen and ensure an optimal balance between efficacy and safety.

01 Mar 2023·International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Integrating antibody drug conjugates in the management of gynecologic cancers

Review

Author: Mahner, Sven ; Coleman, Robert L ; Lorusso, Domenica ; Moore, Kathleen Nadine ; Chelariu-Raicu, Anca

The clinical development of antibody drug conjugates (ADCs) in ovarian cancer began in 2008 with farletuzumab, a humanized monoclonal antibody, and vintafolide, an antigen drug conjugate, both targeting alpha folate receptor. Over the years, this novel class of drugs expanded to agents with a more sophisticated design and structure, targeting tissue factor (TF) in cervical cancer or human epidermal growth factor receptor 2 (HER2) in endometrial cancer. Despite the impressive number of patients included in clinical trials investigating different ADCs across gynecological cancers, it was only recently that the Food and Drug Administration (FDA) granted accelerated approvals to the first ADCs in gynecologic cancer. In September 2021, the FDA approved tisotumab vedotin (TV) in recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This was followed in November 2022, by the approval of mirvetuximab soravtansine (MIRV) for adult patients with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Currently, the field of ADCs is rapidly expanding and more than 20 ADC formulations are in clinical trials for the treatment of ovarian, cervical and endometrial tumors. This review summarizes key evidence supporting their use and therapeutic indications, including results from late-stage development trials investigating MIRV in ovarian cancer and TV in cervical cancer. We also outline new concepts in the field of ADCs, including promising targets such as NaPi2 and novel drug delivery platforms such as dolaflexin with a scaffold-linker. Finally, we briefly present challenges in the clinical management of ADC toxicities and the emerging role of ADC combination therapies, including chemotherapy, anti-angiogenic and immunotherapeutic agents.

14

News (Medical) associated with Farletuzumab

12 Jul 2024

·www.fiercepharma.com

Fierce Pharma Asia—BMS, Eisai's ADC divorce; Takeda's US layoffs; House Speaker's BIOSECURE pledge

Bristol Myers Squibb and Eisai's ADC deal termination, Takeda's planned layoffs in Massachusetts and the U.S. House Speaker's pledge for a vote on the BIOSECURE Act made our news in the past two weeks. After a break for the Fourth of July holiday in the U.S., we're back with two weeks' worth of biopharma news from Asia. During that time, Bristol Myers Squibb returned Eisai's FRα-targeted antibody-drug conjugate. In addition, Takeda telegraphed plans to lay off 220 employees in Massachusetts, while U.S. House Speaker Mike Johnson pledged a full floor vote on the BIOSECURE Act this year. 1. BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival Bristol Myers Squibb has ended its bet on Eisai’s FRα-targeted antibody-drug conjugate, farletuzumab ecteribulin (MORAb-202), which is a potential competitor to AbbVie’s newly bought Elahere. The deal included $460 million upfront, $200 million in R&D support and up to $2.5 billion in milestones, giving BMS joint rights in the U.S. and Europe plus exclusive rights in other countries. Eisai now aims to “accelerate the development of the agent as a high priority.” 2. Takeda to cut another 220 jobs in Massachusetts, as Merck KGaA plots office move Takeda continues to reduce staffing levels in the U.S. amid a restructuring campaign. In Massachusetts, the Japanese pharma said it will cut 190 employees at its Cambridge headquarters and 31 people at its Lexington site, beginning in August. A previous round of 641 cuts was set to begin in early July. 3. House Speaker Mike Johnson pledges vote for BIOSECURE as China-targeting bill hangs in limbo U.S. House Speaker Mike Johnson pledged to advance several China-targeting bills in the remaining term of this Congress. Among them, the House will vote this year on the BIOSECURE Act, Johnson said at an event held by conservative think tank the Hudson Institute. 4. BIOSECURE Act hurts US biopharma industry's confidence in Chinese partners: survey Meanwhile, a L.E.K. survey found that U.S.-based life sciences companies experienced a sharp decline in confidence in working with Chinese partners. Already, 26% of 73 firms surveyed by the consulting firm said they’re looking to shift away from their Chinese partners, even tough only 2% have started the unwinding process. 5. China's share of trials jumps, along with enrollment times: IQVIA report Amid geopolitical turmoil, China’s share of the world’s clinical trials has surpassed Eastern Europe, an IQVIA report shows. The country’s proportion of world trials grew to 15% at the end of 2023, while Eastern Europe’s share declined to 11%. North American trials now make up 23% of the total, a 17% increase from five years ago, while Western Europe’s share fell to 25% of the global total. 6. J&J, Legend's Carvykti shows CAR-T can extend lives in multiple myeloma Johnson & Johnson and Legend Biotech said their Carvykti has shown a statistically significant overall survival benefit in the CARTITUDE-4 trial. Compared with two standard combination therapies, the BCMA CAR-T drug was better at extending the lives of multiple myeloma patients who had tried one to three prior lines of therapy. The latest win puts Carvykti further ahead of Bristol Myers Squibb’s rival, Abecma. 7. Ipsen scores 2nd preclinical ADC via $1B biobucks pact with Foreseen Ipsen has got its hand on a second antibody-drug conjugate this year. In a deal totaling $1.03 billion, the French pharma has obtained exclusive global rights to a preclinical solid tumor candidate by China’s Foreseen Biotechnology. The drug, coded FS001, targets an undisclosed tumor-associated antigen and uses a Topo1 inhibitor as its payload. The target was identified with Foreseen’s AI-powered screening platform. 8. High-flying Samsung Biologics inks $1B production pact with unnamed US pharma Samsung Biologics said it has signed a new manufacturing contract with a large, unnamed U.S. drugmaker worth 1.46 trillion Korean won (about $1.05 billion). The deal represents more than 39% of Samsung Biologics’ total sales from last year and is expected to run through the end of 2030. Other News of Note: 9. Elevar, Hengrui eye quick refile for PD-1 liver cancer combo after surprise FDA rejection 10. China-made injectable PD-L1 drug flunks pivotal trial, forcing US partner to seek strategic options 11. Without Pfizer appeal, Daiichi Sankyo closes long-running ADC patent arbitration with $47M win 12. Ensho emerges with inflammatory disease portfolio from Eisai's EA Pharm 13. CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals 14. Rexulti reclaims TV drug ad spending top spot as Otsuka, Lundbeck eat away at AbbVie’s dominance

ADCAcquisitionPatent InfringementLicense out/in

01 Jul 2024

·pipelinereview.com

Eisai announces move to solo development and commercialization of farletuzumab ecteribulin (Fzec) antibody drug conjugate (ADC)

Strategic collaboration with Bristol Myers Squibb ended TOKYO, Japan I July 01, 2024 I Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. Based on the agreement, Eisai now owns all rights to FZEC and will solely conduct the global development and commercialization of the agent. Eisai will accelerate the development of the agent as a high priority with the hope to deliver it to patients as early as possible. Eisai plans to refund a part of the unused portion of the $200 million payment it received towards research and development expenses from Bristol Myers Squibb under the collaboration agreement and record the remaining as other income. FZEC is Eisai’s first ADC and is composed of Eisai’s in-house developed farletuzumab, a humanized IgG1 monoclonal antibody that binds to the FRα, and Eisai’s in-house developed anticancer agent eribulin, using an enzymatically cleavable linker. Currently, three clinical studies are ongoing: Eisai’s Phase 1/2 study for solid tumors (NCT04300556), and Bristol Myers Squibb’s Phase 2 studies for ovarian, peritoneal and fallopian tube cancers (NCT05613088) and non-small cell lung cancer (NCT05577715). Eisai positions oncology as a key franchise area and aims to contribute toward the cure of cancers by exploring the depths of human biology. FZEC development for refractory cancers is a testament of our dedication to addressing the unmet medical needs of patients with cancer. Eisai will make continuous efforts to increase the benefits provided to patients with cancer and their families. [Notes to editors] 1. Farletuzumab ecteribulin (FZEC, formerly known as MORAb-202) FZEC is Eisai’s first antibody drug conjugate (ADC) and that is composed of Eisai’s in-house developed farletuzumab, a humanized IgG1 monoclonal antibody that binds to the folate receptor alpha (FRα), and Eisai’s in-house developed anticancer agent eribulin, using an enzymatically cleavable linker. After FZEC enters the target FRα-positive cancer cells, it is thought that the linker is enzymatically cleaved, releasing eribulin from the antibody leading to its antitumor activity. When the anticancer agent and antibody components of an ADC are separated inside a targeted antigen-positive cancer cell, it is theorized that the released anticancer agent also has a bystander effect on neighboring antigen-negative cancer cells and the component cells of the tumor microenvironment. In pre-clinical studies, FZEC demonstrated a bystander effect*, with antitumor activity on the FRα-negative cancer cells surrounding the FRα-positive cancer cells. The payload eribulin was the first in the halichondrin class of microtubule dynamics inhibitor. Structurally, eribulin is a simplified and synthetically produced version of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai, and functions by inhibiting the growth phase of microtubule dynamics which prevents cell division. Eribulin has been approved in countries including Japan, the United States, China, in Europe and in Asia for use in the treatment of advanced breast cancer and liposarcoma (soft tissue sarcoma in Japan). *Bystander effect: When the anticancer agent and antibody parts of an ADC are separated inside a targeted antigen-positive cancer cell, the released anticancer agent also affects neighboring antigen-negative cancer cells and the component cells of the cancer microenvironment. SOURCE: Eisai

License out/inADCPhase 2Drug ApprovalPhase 1

01 Jul 2024

·www.fiercebiotech.com

BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival

Eisai will “accelerate the development of the agent as a high priority.” Bristol Myers Squibb is walking away from its $650 million bet on an Eisai antibody-drug conjugate (ADC). The Japanese drugmaker said BMS decided to end the co-development agreement as part of an ongoing portfolio prioritization push. BMS partnered with Eisai in 2021, paying $450 million upfront for rights to MORAb-202. Eisai, which had phase 1 data from 22 patients at the time of the deal, conjugated an anti-folate receptor alpha (FRα) antibody and anticancer agent to create the candidate. BMS paid the upfront, plus $200 million in R&D support, and dangled $2.5 billion in milestones to land the deal. Three years later, BMS has decided the candidate is no longer part of its plans. The Big Pharma had joint rights to MORAb-202 in markets including the U.S. and Europe, plus exclusive rights in other parts of the world. Eisai has regained full rights to the ADC, which is now called farletuzumab ecteribulin (FZEC), and plans to refund “a part of the unused portion of the $200 million” BMS paid to support R&D costs. The Japanese drugmaker said it will “accelerate the development of the agent as a high priority.” BMS began two phase 2 trials, one in ovarian, peritoneal and fallopian tube cancers and another in non-small cell lung cancer, in 2022. Both studies have passed their estimated primary completion dates but are still listed as recruiting on ClinicalTrials.gov. BMS cut its enrollment targets and dropped a dose in both trials. The indications targeted in the phase 2 trial reflect evidence that FRα is highly expressed in patients with certain types of solid tumors. Using an antibody to direct a cytotoxic payload to those targets could drive the destruction of the tumors and spare healthy tissues. Eisai is also still running a phase 1/2 study in solid tumors that began in 2020. Since striking the deal, BMS has seen ImmunoGen win approval for the rival FRα-directed ADC Elahere and sell up to AbbVie for $10.1 billion. Other companies are lining up to challenge Elahere. Genmab joined the chasing pack earlier this year when it agreed to buy ProfoundBio for $1.8 billion. In April, BMS unveiled plans for a significant “pipeline rationalization” that would see the Big Pharma lay off over 2,000 staff this year and end work on about a dozen programs, including CTLA4- , SIRPα- and BET-targeting meds. “Throughout the year we'll continue to look at these same principles and see what else we need to take out from our pipeline and either externalize it or not be able to develop it further,” Chief Medical Officer Samit Hirawat, M.D., said at the time.

Phase 1ADCPhase 2License out/inAcquisition

100 Deals associated with Farletuzumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09343	Farletuzumab	-	DB05595

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent ovarian cancer	Phase 3	Belgium	Morphotek, Inc.	20 Sep 2010
Recurrent Platinum-Resistant Ovarian Carcinoma	Phase 3	Belgium	Morphotek, Inc.	20 Sep 2010
Platinum-Sensitive Ovarian Carcinoma	Phase 3	United States	Morphotek, Inc.	16 Apr 2009
Platinum-Sensitive Ovarian Carcinoma	Phase 3	United States	Eisai Europe Ltd.	16 Apr 2009
Platinum-Sensitive Ovarian Carcinoma	Phase 3	Japan	Morphotek, Inc.	16 Apr 2009
Platinum-Sensitive Ovarian Carcinoma	Phase 3	Japan	Eisai Europe Ltd.	16 Apr 2009
Platinum-Sensitive Ovarian Carcinoma	Phase 3	Argentina	Eisai Europe Ltd.	16 Apr 2009
Platinum-Sensitive Ovarian Carcinoma	Phase 3	Argentina	Morphotek, Inc.	16 Apr 2009
Platinum-Sensitive Ovarian Carcinoma	Phase 3	Australia	Eisai Europe Ltd.	16 Apr 2009
Platinum-Sensitive Ovarian Carcinoma	Phase 3	Australia	Morphotek, Inc.	16 Apr 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02289950 (Pubmed)	Phase 2	Platinum-Sensitive Ovarian Carcinoma	214	Farletuzumab+Chemotherapy	kuhazqjkjt(oharccongc) = xvzunpuojs cdypbmeota (eghailxqyv )	Negative	07 Feb 2023
				Placebo+Chemotherapy	kuhazqjkjt(oharccongc) = xonmwsgpgi cdypbmeota (eghailxqyv )
NCT00849667 (CTgov)	Phase 3	Platinum-Sensitive Ovarian Carcinoma	1,100	Taxane+Carboplatin+Farletuzumab (1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin)	bvxrlrjtzj(xykcnifkvu) = stojnleqep wegaetjgfx (xzdoozjzfn, sfstdhgylx - vdldoafbjo) View more	-	30 Dec 2022
				Taxane+Carboplatin+Farletuzumab (2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin)	bvxrlrjtzj(xykcnifkvu) = lzsuamkzuv wegaetjgfx (xzdoozjzfn, ooxixztyjy - afagccarmg) View more
NCT01018563 (CTgov)	Phase 2	Platinum-sensitive epithelial ovarian cancer \| Ovarian Epithelial Carcinoma	3	Farletuzumab (Farletuzumab 62.5 mg/m^2)	wuumargdmi = impxoonivc hldsqbpfmw (qwtrvsqejo, bomzplwrcs - tfycgotlpm) View more	-	08 Dec 2021
				Farletuzumab (Farletuzumab 100 mg/m^2)	xwdeowpwjc = ltzxrjhozo bxhbvvysek (chqrefcdju, caqpoeuvlp - fvtczjrwei) View more
NCT02289950 (CTgov)	Phase 2	Platinum-Sensitive Ovarian Carcinoma \| Ovarian Epithelial Carcinoma	332	PLD+Paclitaxel+Carboplatin+Farletuzumab (Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD)	eoanmdvtpj(ymqfzspoeu) = qjlkveqxdc oyoozzrfio (wygrpmtarb, pstxiuhoef - tlpsbyaxeb) View more	-	02 Sep 2021
				PLD+Paclitaxel+Carboplatin (Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD)	eoanmdvtpj(ymqfzspoeu) = ikmijubbjk oyoozzrfio (wygrpmtarb, hfqrhikozz - ksmxazbvxs) View more
NCT01218516 (CTgov)	Phase 2	Adenocarcinoma of Lung	130	Placebo (Combination Therapy: Placebo + Chemotherapy)	dzpqkorxjq(fapguqcdhx) = xqbibdgdro iyvweliejw (sedgwizxuh, grhzthmkyy - fzeylroqjn) View more	-	20 Aug 2020
				Farletuzumab (Combination Therapy: Farletuzumab + Chemotherapy)	dzpqkorxjq(fapguqcdhx) = zqobzsmsdc iyvweliejw (sedgwizxuh, rezfvchrrn - ystfhpytyk) View more
NCT00738699 (FAR-122, CTgov)	Phase 2	Recurrent Platinum-Resistant Ovarian Carcinoma	415	Paclitaxel+MORAb-003 (Farletuzumab) (MORAb-003 (Farletuzumab) Plus Paclitaxel)	trxsffnjer(eyoixllxrm) = ncuntwvjin mqgezzapjf (ownweddvxg, tqznspufly - fafhqbngja) View more	-	30 Mar 2017
				Placebo+Paclitaxel (Placebo (Normal Saline) Plus Paclitaxel)	trxsffnjer(eyoixllxrm) = nogxyucagv mqgezzapjf (ownweddvxg, wkpamhyqrc - tezdkqllsd) View more
NCT01004380 (Pubmed \| Obstet Gynecol Surv) Manual	Phase 1	Platinum-sensitive epithelial ovarian cancer	15	farletuzumab+carboplatin+pegylated liposomal doxorubicin	xglkqlpbiw(xuiybczkos) = lgzrfvatup gnruhsznzi (ijtjhhuxfg ) View more	Positive	01 Feb 2016
NCT01049061 (Pubmed \| Invest New Drugs) Manual	Phase 1	Solid tumor	16	farletuzumab	qzjcwkrjai(ryydsytbkr) = Neither DLTs nor grade 3/4 toxicities were reported in all cohorts hqshzwmxbt (jlmevndlsw ) View more	Positive	01 Apr 2015
WCLC2013	Not Applicable	Non-Small Cell Lung Cancer	130	Farletuzumab 7.5 mg/kg	tydngapcrr(htmtaivdna) = ylliikpowe qljtxckfbn (lbsourfwxh )	Negative	28 Oct 2013
				Placebo	tydngapcrr(htmtaivdna) = nxwyrrltpd qljtxckfbn (lbsourfwxh )
NCT00318370 (CTgov)	Phase 2	Platinum-sensitive epithelial ovarian cancer \| Primary Peritoneal Serous Adenocarcinoma \| Peritoneal Neoplasms ... View more	58	Farletuzumab (Far Only)	xtpwloxrxx = vrhotaehuu rttolrqdgz (nklqaqwgfm, pyhgphzzei - mfxlgsplxk)	-	15 Feb 2012
				Chemo Plus Far (Chemo Plus Far)	lrewmrbgkn = suboxrnozb rlqtnkaetg (agecqkmojr, vtlqnvgjpu - jdzaeykoqf) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Farletuzumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation